Artificial intelligence (AI) is the most revolutionizing development in the health care industry in the current decade, with diagnostic imaging having the greatest share in such development. Machine learning and deep learning (DL) are subclasses of AI that show breakthrough performance in image analysis. They have become the state of the art in the field of image classification and recognition. Machine learning deals with the extraction of the important characteristic features from images, whereas DL uses neural networks to solve such problems with better performance. In this review, we discuss the current applications of machine learning and DL in the field of diagnostic radiology. Deep learning applications can be divided into medical imaging analysis and applications beyond analysis. In the field of medical imaging analysis, deep convolutional neural networks are used for image classification, lesion detection, and segmentation. Also used are recurrent neural networks when extracting information from electronic medical records and to augment the use of convolutional neural networks in the field of image classification. Generative adversarial networks have been explicitly used in generating high-resolution computed tomography and magnetic resonance images and to map computed tomography images from the corresponding magnetic resonance imaging. Beyond image analysis, DL can be used for quality control, workflow organization, and reporting. In this article, we review the most current AI models used in medical imaging research, providing a brief explanation of the various models described in the literature within the past 5 years. Emphasis is placed on the various DL models, as they are the most state-of-art in imaging analysis.
Deep learning reconstruction CT algorithms can reduce image noise associated with lower radiation doses while preserving image texture and diagnostic performance, often overcoming the limitations of filtered backprojection and iterative reconstruction methods, and future DLR software developments combined with new CT hardware technologies such as photon-counting CT promise dramatically improved image quality.
Magnetic resonance (MR)-guided radiation therapy (RT) is enhancing head and neck cancer (HNC) treatment through superior soft tissue contrast and longitudinal imaging capabilities. However, manual tumor segmentation remains a significant challenge, spurring interest in artificial intelligence (AI)-driven automation. To accelerate innovation in this field, we present the Head and Neck Tumor Segmentation for MR-Guided Applications (HNTS-MRG) 2024 Challenge, a satellite event of the 27th International Conference on Medical Image Computing and Computer Assisted Intervention. This challenge addresses the scarcity of large, publicly available AI-ready adaptive RT datasets in HNC and explores the potential of incorporating multi-timepoint data to enhance RT auto-segmentation performance. Participants tackled two HNC segmentation tasks: automatic delineation of primary gross tumor volume (GTVp) and gross metastatic regional lymph nodes (GTVn) on pre-RT (Task 1) and mid-RT (Task 2) T2-weighted scans. The challenge provided 150 HNC cases for training and 50 for final testing hosted on grand-challenge.org using a Docker submission framework. In total, 19 independent teams from across the world qualified by submitting both their algorithms and corresponding papers, resulting in 18 submissions for Task 1 and 15 submissions for Task 2. Evaluation using the mean aggregated Dice Similarity Coefficient showed top-performing AI methods achieved scores of 0.825 in Task 1 and 0.733 in Task 2. These results surpassed clinician interobserver variability benchmarks, marking significant strides in automated tumor segmentation for MR-guided RT applications in HNC.
13 June 2024 in Diagnostic and Interventional Radiology
There have been rapid advancements in cancer treatment in recent years, including targeted molecular therapy and the emergence of anti-angiogenic agents, which necessitate the need to quickly and accurately assess treatment response. The ideal tool is robust and non-invasive so that the treatment can be rapidly adjusted or discontinued based on efficacy. Since targeted therapies primarily affect tumor angiogenesis, morphological assessment based on tumor size alone may be insufficient, and other imaging modalities and features may be more helpful in assessing response. This review aims to discuss the biological principles of tumor angiogenesis and the multi-modality imaging evaluation of anti-angiogenic therapeutic responses.
1 August 2021 in Clinical Neurology and Neurosurgery